BRIDGEWATER -
The corporate name change is based on the Greek word 'tharros', translated to mean courage and reflects the transformation of the Company into a patient-focused, clinical development organization. The Company's common stock will trade on The Nasdaq Capital Market under a new ticker symbol, THAR, effective as of
'Over the past few months, we have made significant progress in shifting the focus of the Company to align with our future vision to impact patients in serious need of new treatment options,' said
Tharimmune is progressing towards acquiring a clinical stage asset, TH104, with a recently approved IND. TH104 has a dual mechanism of action by affecting multiple receptors, known to suppress chronic, debilitating pruritis or 'uncontrollable itching'. The Company expects to close the acquisition in the fourth quarter as well launch and complete a phase 1 pharmacokinetic trial by year-end. The clinical data package is strengthened by the phase 1 clinical trials already conducted ex-US, which showed reliable bioavailability of the active ingredient in TH104 via transmucosal film technology in both healthy volunteers as well as people diagnosed with liver disease, including primary biliary cholangitis.
About
Forward Looking Statements
Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified using words such as 'anticipate,' 'believe,' 'forecast,' 'estimated' and 'intend' or other similar terms or expressions that concern Hillstream's expectations, strategy, plans or intentions. These forward-looking statements are based on Hillstream's current expectations and actual results could differ materially. There are several factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, clinical trials involve a lengthy and expensive process with an uncertain outcome, and results of earlier studies and trials may not be predictive of future trial results; our clinical trials may be suspended or discontinued due to unexpected side effects or other safety risks that could preclude approval of our product candidates; risks related to business interruptions which could seriously harm our financial condition and increase our costs and expenses; dependence on key personnel; substantial competition; uncertainties of patent protection and litigation; dependence upon third parties and risks related to failure to obtain
Contact:
Email: ir@tharimmune.com
Web: www.tharimmune.com
(C) 2023 Electronic News Publishing, source